# Garsorasib

Source: https://onco.cc/drugs/garsorasib/  
OnCo record `garsorasib` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Garsorasib is InventisBio's KRAS G12C-blocking pill, approved in China in 2024 for previously treated lung cancer with that mutation.

## Summary

Approved by the NMPA in August 2024 for KRAS G12C-mutant advanced NSCLC after prior systemic therapy, on a single-arm phase 2 trial that followed the phase 1 study published in the Journal of Thoracic Oncology in 2023. With fulzerasib it made China the second market with domestic KRAS G12C inhibitors; combination studies with EGFR antibodies and SHP2 inhibitors are under way.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-10
- Tags: china
- Code: D-1553
- Modality: Small-molecule covalent KRAS G12C inhibitor
- Mechanism: Covalent KRAS G12C inhibitor binding the switch II pocket of the GDP-bound mutant protein.
- Approvals: China 2024: KRAS G12C-mutant advanced NSCLC after at least one systemic therapy

## Sources

- InventisBio: https://www.inventisbio.com/
- D-1553 phase 1 (J Thorac Oncol 2023): https://doi.org/10.1016/j.jtho.2023.03.015
- NMPA (National Medical Products Administration): https://www.nmpa.gov.cn

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/), [SHP2 (PTPN11)](https://onco.cc/targets/shp2/)
- companies: [InventisBio](https://onco.cc/companies/inventisbio/)
- pathways: [RAS / RAF / MEK / ERK (MAPK)](https://onco.cc/pathways/ras-mapk/)
- terms: [KRAS mutation subtypes (G12C, G12D, G12V)](https://onco.cc/terms/kras-mutation-subtypes/)
- trials: [A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment](https://onco.cc/trials/nct07601048/), [D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standar](https://onco.cc/trials/nct06300177/), [Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors](https://onco.cc/trials/nct05379946/), [Study to Evaluate D-1553 in Subjects With Solid Tumors](https://onco.cc/trials/nct04585035/)
- key papers: [D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results](https://onco.cc/key-papers/paper-li-j-thorac-oncol/)

---
JSON: https://onco.cc/api/v1/entities/garsorasib.json